ClinicalTrials.gg
CompletedNCT01562158Updated Jan 11, 2017

Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Allogeneic Stem Cell Transplantation

A Phase 2 interventional study of standard therapy and activated recombinant human factor VII in Acquired Bleeding Disorder and Bleeding During/Following Surgery, sponsored by Novo Nordisk A/S. Completed at 46 sites in 16 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2017-01-11.

Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Study summary

This trial is conducted in Asia, Europe and Oceania. The aim of this trial is to evaluate the efficacy of placebo and activated recombinant human factor VII in patients having undergone allogeneic or autologous stem cell transplantation.

02

Conditions studied

  • Acquired Bleeding Disorder
  • Bleeding During/Following Surgery
03

In context

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who have undergone or autologous stem cell transplantation

Exclusion criteria

Exclusion Criteria:

  • Known or suspected allergy to trial product
  • Participation in other trials with unapproved drugs or trials with equal or similar objective
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
100 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Procedure: standard therapy · Drug: placebo

  • Experimental
    Low dose

    Procedure: standard therapy · Drug: activated recombinant human factor VII

  • Experimental
    Medium dose

    Procedure: standard therapy · Drug: activated recombinant human factor VII

  • Experimental
    High dose

    Procedure: standard therapy · Drug: activated recombinant human factor VII

Interventions

06

What researchers measure

Primary outcomes

  1. Effect on bleeding, defined as change in bleeding score

Secondary outcomes

  1. Transfusion requirements

  2. Bleeding evaluation

  3. Adverse events

07

Study locations

46 sites
  • Novo Nordisk Investigational Site
    Chapel Hill, North Carolina 27599-7035, United States
  • Novo Nordisk Investigational Site
    Herston, 4029, Australia
  • Novo Nordisk Investigational Site
    Parkville, 3050, Australia
  • Novo Nordisk Investigational Site
    Westmead, 2145, Australia
  • Novo Nordisk Investigational Site
    Vienna, A -1090, Austria
  • Novo Nordisk Investigational Site
    København, 2100, Denmark
  • Novo Nordisk Investigational Site
    Helsinki, 00029, Finland
  • Novo Nordisk Investigational Site
    Besancon, 25030, France
  • Novo Nordisk Investigational Site
    Lille, 59037, France
  • Novo Nordisk Investigational Site
    Tours, 37044, France
  • Novo Nordisk Investigational Site
    Dresden, 01307, Germany
  • Novo Nordisk Investigational Site
    Hamburg, 20246, Germany
  • Novo Nordisk Investigational Site
    Hannover, 30625, Germany
  • Novo Nordisk Investigational Site
    Idar-Oberstein, 55743, Germany
  • Novo Nordisk Investigational Site
    Köln, 50924, Germany
  • Novo Nordisk Investigational Site
    München, 81377, Germany
  • Novo Nordisk Investigational Site
    Regensburg, 93042, Germany
  • Novo Nordisk Investigational Site
    Tübingen, 72076, Germany
  • Novo Nordisk Investigational Site
    Wiesbaden, 65191, Germany
  • Novo Nordisk Investigational Site
    Haifa, 31096, Israel
  • Novo Nordisk Investigational Site
    Jerusalem, 91120, Israel
  • Novo Nordisk Investigational Site
    Firenze, 50134, Italy
  • Novo Nordisk Investigational Site
    Genova, 16132, Italy
  • Novo Nordisk Investigational Site
    Pesaro, 61100, Italy
  • Novo Nordisk Investigational Site
    Rome, 00144, Italy
  • Novo Nordisk Investigational Site
    Udine, 33100, Italy
  • Novo Nordisk Investigational Site
    Gdansk, 80-952, Poland
  • Novo Nordisk Investigational Site
    Katowice, 40-029, Poland
  • Novo Nordisk Investigational Site
    Poznan, 60-569, Poland
  • Novo Nordisk Investigational Site
    Warszawa, 00-909, Poland
  • Novo Nordisk Investigational Site
    Warszawa, 02-097, Poland
  • Novo Nordisk Investigational Site
    Wroclaw, 50-345, Poland
  • Novo Nordisk Investigational Site
    Wroclaw, 53-439, Poland
  • Novo Nordisk Investigational Site
    Singapore, 169608, Singapore
  • Novo Nordisk Investigational Site
    Barcelona, 08036, Spain
  • Novo Nordisk Investigational Site
    Santander, 39008, Spain
  • Novo Nordisk Investigational Site
    Valencia, 46026, Spain
  • Novo Nordisk Investigational Site
    Göteborg, 413 45, Sweden
  • Novo Nordisk Investigational Site
    Stockholm, 141 86, Sweden
  • Novo Nordisk Investigational Site
    Uppsala, 751 85, Sweden
  • Novo Nordisk Investigational Site
    Basel, 4031, Switzerland
  • Novo Nordisk Investigational Site
    Zürich, 8091, Switzerland
  • Novo Nordisk Investigational Site
    Bangkok, 10330, Thailand
  • Novo Nordisk Investigational Site
    Bangkok, Thailand
  • Novo Nordisk Investigational Site
    London, W12 OHS, United Kingdom
  • Novo Nordisk Investigational Site
    Manchester, M20 4BX, United Kingdom
08

References and documents

Publications

  • Pihusch M, Bacigalupo A, Szer J, von Depka Prondzinski M, Gaspar-Blaudschun B, Hyveled L, Brenner B; F7BMT-1360 Trial Investigators. Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation. J Thromb Haemost. 2005 Sep;3(9):1935-44. doi: 10.1111/j.1538-7836.2005.01523.x. PubMed 16102099 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2001, a primary completion of Oct 2003 and a completion of Oct 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2012
First posted
Mar 23, 2012
Start
Apr 2001
Primary completionActual
Oct 2003
CompletionActual
Oct 2003
Last update
Jan 11, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01562158
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Mar 23, 2012
Start date
Apr 2001
Primary completion
Oct 2003
Completion
Oct 2003
Last update
Jan 11, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Recombinant FVIIa

Start the discussion